SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials, The Lancet, vol.393, issue.10166, pp.31-39, 2019. ,
Use of sodium?glucose co?transporter?2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure, European Journal of Heart Failure, vol.22, issue.4, pp.604-617, 2020. ,
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis, The Lancet Diabetes & Endocrinology, vol.7, issue.11, pp.845-854, 2019. ,
SGLT2 Inhibitors Produce Cardiorenal Benefits by Promoting Adaptive Cellular Reprogramming to Induce a State of Fasting Mimicry: A Paradigm Shift in Understanding Their Mechanism of Action, Diabetes Care, vol.43, issue.3, pp.508-511, 2020. ,
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction, New England Journal of Medicine, vol.381, issue.21, pp.1995-2008, 2019. ,
Correction to: Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF, Circulation, vol.142, issue.20, pp.1995-2008, 2020. ,
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes, JAMA, vol.323, issue.14, p.1353, 2020. ,
Zannad F; EMPEROR-Reduced Trial Committees and Investigators. Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial, Eur J Heart Fail, vol.21, pp.1270-1278, 2019. ,
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure, New England Journal of Medicine, vol.383, issue.15, pp.1413-1424, 2020. ,
URL : https://hal.archives-ouvertes.fr/hal-03014260
CHARM Investigators and Committees. Prevalence of prediabetes and undiagnosed diabetes in patients with HFpEF and HFrEF and associated clinical outcomes, Cardiovasc Drugs Ther, vol.31, pp.545-549, 2017. ,
Risk Related to Pre?Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction, Circulation: Heart Failure, vol.9, issue.1, p.2560, 2016. ,
Insulin-Resistant Cardiomyopathy, Journal of the American College of Cardiology, vol.51, issue.2, pp.93-102, 2008. ,
Insulin resistance and dysglycemia are associated with left ventricular remodeling after myocardial infarction in non-diabetic patients, Cardiovascular Diabetology, vol.18, issue.1, p.100, 2019. ,
Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices, European Journal of Heart Failure, vol.13, issue.2, pp.195-199, 2011. ,
Impaired fasting glucose and development of chronic kidney disease in non-diabetic population: a Mendelian randomization study, BMJ Open Diabetes Res Care, vol.8, p.1395, 2020. ,
Influence of Prediabetes on the Effects of Intensive Systolic Blood Pressure Control on Kidney Events, American Journal of Hypertension, vol.32, issue.12, pp.1170-1177, 2019. ,